Evidence map›Paper›PMID 32524293›Full record

Observational studyJournal of cancer research and clinical oncology2020

Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.

Masakazu Yamamoto, Ikuko Suzuki, Kouji Saitou, Riko Tsumanuma, Shuhei Okuyama, Hiroaki Kumagai, Eijiro Omoto, Shinji Satoh, Katsushi Tajima

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Masakazu YamamotoDepartment of Neurology, Hematology, Metabolism, Endocrinology and Diabetology, Yamagata University School of Medicine, Yamagata, Japan.
Ikuko SuzukiDepartment of Hematology, Okitama Public General Hospital, Yamagata, Japan.
Kouji SaitouWorking Group of Chemotherapy of Hematology, Okitama Public General Hospital, Yamagata, Japan.
Riko TsumanumaDepartment of Hematology, Yamagata Prefectural Central Hospital, 1800, Aoyagi, Yamagata, 990-2292, Japan.
Shuhei OkuyamaDepartment of Hematology, Yamagata Prefectural Central Hospital, 1800, Aoyagi, Yamagata, 990-2292, Japan.
Hiroaki KumagaiDepartment of Hematology, Yamagata Prefectural Central Hospital, 1800, Aoyagi, Yamagata, 990-2292, Japan.
Eijiro OmotoDepartment of Hematology, Yamagata Prefectural Central Hospital, 1800, Aoyagi, Yamagata, 990-2292, Japan.
Shinji SatohDepartment of Hematology, Okitama Public General Hospital, Yamagata, Japan.
Katsushi TajimaDepartment of Hematology, Yamagata Prefectural Central Hospital, 1800, Aoyagi, Yamagata, 990-2292, Japan. katsushitajima@ypch.gr.jp.ORCID http://orcid.org/0000-0003-4339-9181
Yamagata Prefectural Central Hospital · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComorbidity and relative dose intensity (RDI) have been associated with survival in diffuse large B-cell lymphoma (DLBCL) patients, but both relationships remain unaddressed in the same patients.

methodsA retrospective review of consecutive DLBCL patients treated from January 2010 to October 2018 was performed. Data for the clinical characteristics of the patients, including the Charlson Comorbidity Index (CCI) and RDI, on their outcomes were evaluated.

resultsA total of 211 patients with a median age of 72 years (range 19-90 years) were analyzed. CCI ≥ 2 was associated with poor event-free survival (EFS) and overall survival (OS). RDI < 70% was associated with worse EFS and OS. A multivariate analysis revealed that RDI < 70% was only a poor risk factor for the reduction of OS in elderly DLBCL patients (65 years <) and independent from the presence of CCI. The relationship between CCI and RDI in elderly patients was analyzed in four groups, based on CCI ≥ 2 or less and RDI ≥ 70% or less. The group with CCI ≥ 2 and RDI < 70% had a poorer OS and EFS, as compared to the other three groups. The group with CCI < 2 and RDI ≥ 70% had a superior OS but an identical EFS, as compared to the two groups with CCI < 2 and RDI < 70% and CCI ≥ 2 and RDI ≥ 70%.

conclusionsCCI ≥ 2 was associated with a poorer outcome, but maintaining RDI ≥ 70% may improve the outcome, especially in elderly DLBCL patients.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDoxorubicinFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneProgression-Free SurvivalRituximabTreatment OutcomeCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineComorbidityDiffuse large B-cell lymphomaElderlyRelative dose intensity

Identifiers

PMID32524293
PMCPMC11804282
OpenAlexW3033623718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.